scispace - formally typeset
K

Keith M. Sullivan

Researcher at Duke University

Publications -  458
Citations -  40788

Keith M. Sullivan is an academic researcher from Duke University. The author has contributed to research in topics: Transplantation & Total body irradiation. The author has an hindex of 105, co-authored 447 publications receiving 39067 citations. Previous affiliations of Keith M. Sullivan include American Cancer Society & Boston Children's Hospital.

Papers
More filters
Journal ArticleDOI

Low serum thymic hormone levels in patients with chronic graft-versus-host disease

K Atkinson, +17 more
- 01 May 1982 - 
TL;DR: Findings show that thymic epithelial secretory function is impaired in chronic GVHD, and this may in part be responsible for the immunodeficiency characteristic of these patients.
Journal Article

Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.

M. Siadak, +2 more
- 01 Jul 1994 - 
TL;DR: IVIG has shown benefit in reducing septicaemia, interstitial pneumonia, fatal cytomegalovirus (CMV) disease, acute GVHD and transplant-related mortality in adult recipients of related marrow transplants and further investigation into dose, schedule and duration of IVIG prophylaxis needs to be conducted.
Journal ArticleDOI

Intravenous Ketorolac in the Emergency Department Management of Sickle Cell Pain and Predictors of Its Effectiveness

Beiter Jl, +4 more
- 01 Apr 2001 - 
TL;DR: First-line therapy with IV ketorolac and IV fluids resulted in adequate resolution of pain in 53% of episodes with acute VOP, and a reported 4 or more painful sites and an initial VAS score greater than 70 were predictors of the likelihood to need additional IV analgesics.

Graft-versus-host disease: allo- and autoimmunity after bone marrow transplantation.

Howard M. Shulman, +1 more
Journal ArticleDOI

Treatment of non-Hodgkin's lymphoma with chemoradiotherapy and allogenic marrow transplantation.

F R Appelbaum, +11 more
- 02 Nov 2007 - 
TL;DR: Twenty patients with disseminated non‐Hodgkin's lymphoma who failed conventional combination chemotherapy were treated with high‐dose chemoradiotherapy and marrow transplantation from an HLA‐identical sibling and four patients remain alive in complete remission from 153 to 784 days after transplant.